Table 2.
Patient and tumor characteristics of patients with DCIS and invasive cancer in the COVID-19 registry
| DCIS [N = 484 patients] |
Invasive cancer [N = 2307 patients] |
|
|---|---|---|
| Mean age, years (SD) | 62 (11.2) | 63 (12.9) |
| Race | ||
| African American | 55 (11.4) | 197 (8.5) |
| Asian | 21 (4.3) | 59 (2.6) |
| Caucasian | 356 (73.6) | 1781 (77.2) |
| Hispanic | 35 (7.2) | 161 (7) |
| Other | 17 (3.5) | 109 (4.7) |
| Telehealth visit [any] | 34 (7.1) | 139 (6.0) |
| Mean tumor size [cm] | 2.4 | 2.1 |
| Estrogen-positive | 394 (84) | 1731 (77.1) |
| HER2-positive/any estrogen | NA | 286 (12.7) |
| Triple-negative | NA | 229 (10.2) |
| Node positive/bilateral | NA | 411 (17.8) |
| Bilateral breast cancer | NA | 107 (4.6) |
| COVID-19 + [any time] | 9 (1.3) | 31 (1.7) |
Data are expressed as n (%) unless otherwise specified
DCIS ductal carcinoma in surgery, COVID-19 coronavirus disease 2019, SD standard deviation, HER2 human epidermal growth factor receptor, NA not applicable